Plaque Psoriasis

This research provides an early analysis of plaque psoriasis patients within routine clinical practice settings and outside of a clinical trial setting.

Individuals with intermediate polysocial risk scores had a 1.2 times higher risk of developing psoriasis, while those with high polysocial risk scores had a 1.5 times higher risk.

A randomized trial examining acupuncture in people with CSU suggests use of acupuncture could improve UAS7 scores in these patients, but investigators noted this failed to reach the threshold for significance.

Results showed significant improvements in serum HDL, CRP, and ESR after treatment with biologic therapies

Expert dermatologist comments on initiating conversations about the safety of IL-23 inhibitors with patients with plaque psoriasis, highlighting biologic-naive patients.

Expert dermatologists review the efficacy of IL-23 inhibitors for plaque psoriasis in the real world, highlighting the opportunity to individualize treatment.

Expert dermatologist Dr Linda Stein Gold discusses the pathophysiology of psoriasis as target for treatment.

Dr Linda Stein Gold discusses the effect that plaque psoriasis in special areas can have on the quality of life of a patient.

Expert dermatologists share how the understanding of the pathophysiology of plaque psoriasis guides approaches to therapy.

Drs Bruce Strober, Benjamin Lockshin, and Jennifer Soung discuss how plaque psoriasis impacts a patient’s quality of life, focusing on patient-reported outcome measurements as well as special areas affected by plaque psoriasis.

Secukinumab (Cosentyx) becomes the first IL-17A inhibitor, as well as the first drug since 2015, approved to treat adults with moderate to severe HS.

Guselkumab effectively cleared the skin of patients with moderate-to-severe plaque psoriasis across all skin tones, with significant improvements observed within the first 16 weeks of treatment.

Experts share practice pearls for managing patients with plaque psoriasis, highlighting the need to educate health care providers about any dermatologic therapy before they commit to treating a patient.

Experts discuss access to treatment as one of the biggest barriers in plaque psoriasis and highlight the importance of individualizing therapy for each patient.

Patients with moderate to severe scalp psoriasis treated with tildrakizumab exhibited sustained efficacy through week 52, demonstrating the long-term effectiveness and safety profile of this treatment.

Patients in the deucravacitinib group had higher response rates compared with placebo at week 16, regardless of the extent of baseline PASI score or BSA involvement.

Patients with scalp and body psoriasis who used nonsteroidal roflumilast foam .3% once daily experienced significant symptom improvement as early as 2 weeks.

Dr. Song spoke in this segment of his interview on several more insightful elements from his presentation titled ‘Early Dermatology Practice Pearls.’

Patients with plaque psoriasis, including in intertriginous areas and genitalia, experienced rapid improvement when treated with tapinarof cream 1%, offering an effective and well-tolerated nonsteroidal option for this condition.

Tildrakizumab significantly improved work productivity and reduced work activity impairment in patients with moderate to severe plaque psoriasis, highlighting this treatment's quality of life benefits.

Secukinumab treatment resulted in greater improvements compared with placebo at week 12, with responses increasing through week 52.

Results from the POETYK PSO-1 trial showed significantly greater improvements in patients receiving deucravacitinib compared with placebo or apremilast.

Linda Stein Gold, MD, explains how the safety considerations of nonsteroidal topicals must be weighed against their significant value in the treatment arsenal.

Linda Stein Gold, MD, discusses the notable transition in topical therapies for both psoriasis and atopic dermatitis, with the introduction of effective FDA-approved nonsteroidal treatments.

In this interview, Dr. Chovatiya touched on several important updates and recent developments in the JAK inhibitor space for dermatologists.